Cost-effectiveness of antenatal fetal surveillance for medication-controlled gestational diabetes

Published: 8 April 2024| Version 1 | DOI: 10.17632/hckwmftryd.1
Chloe Ramirez Biermann


Retrospective chart review investigating the cost-effectiveness of initiating antenatal surveillance in medication-controlled gestational diabetes at 36 weeks rather than 32 weeks.


Steps to reproduce

Patients with gestational diabetes were identified from our ultrasound software database (AS software). Demographic and clinical outcome data were abstracted by both electronic query and individual chart review of the electronic medical record. After determining how many BPPs were performed, we calculated total surveillance costs for all gestational ages, total costs between 32-36 weeks, and total costs after 36 weeks. We divided these costs by the number of observed stillbirths for the cost ($) per stillbirth avoided, and by the number of clinical decisions that were intended to avoid stillbirth for the cost ($) per decision to avoid stillbirth. We calculated these costs for the separate insurance subgroups of private insurance, public insurance, and no insurance from a third-party payer perspective.


University of Kansas Medical Center


Obstetrics, Health Economics, Gestational Diabetes, Fetal Surveillance